SkinBioTherapeutics is a life science company that focuses on skin health through its proprietary platform technology, SkinBiotix®. This technology is based on research conducted by Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester. SkinBiotix® utilizes lysates from probiotic bacteria, which have demonstrated the ability to enhance skin barrier integrity by promoting the formation of tight junctions. These tight junctions are crucial for sealing the spaces between gut cells, thereby preventing the passage of harmful toxins and pathogens. Additionally, the technology has been shown to increase the rate of skin healing and protect the skin from infections by outcompeting harmful microorganisms.

The company is also actively engaged in research to explore the potential of its products across various healthcare sectors, including cosmetics, food supplements, medical devices, hospital and domestic surface hygiene, and pharmaceuticals. SkinBioTherapeutics aims to validate its technology through human studies, with a particular focus on addressing chronic skin conditions such as psoriasis. Their recent consumer study, the BRIGHT study, aims to assess the effectiveness of their AxisBiotix-Ps™ gut-skin health supplement, which has already shown promising results in improving skin conditions for a significant portion of participants.

United Kingdom

SkinBioTherapeutics is a life science company focused on skin health. SkinBioTherapeutics is targeting five specific healthcare sectors: Cosmetic, Food Supplements, Medical Devices, Hospital and Domestic Surface Hygiene and Pharmaceuticals.

SkinBioTherapeutics

Company Details